NCT07105111RecruitingPhase 4
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Source: ClinicalTrials.gov · Last updated 18 Sept 2026
Brief summary (registry, in English)
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 29 Jul 2025
- Start date
- 29 Aug 2025
- Primary completion date
- Jun 2028
- Lead sponsor
- Neurocrine Biosciences
- Diseases
- Schizophrenia, Depression, Bipolar disorder
- NCT number
- NCT07105111
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From 29 Aug 2025 to the primary completion date, Jun 2028
- 19 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of moderate or severe substance use disorder in the last 6 months
Lab values
- History of long QT syndrome, cardiac arrythmia, or severe hepatic impairment
Other
- Have comorbid Parkinsonism or abnormal involuntary movement(s) that is more prominent than TD
Who the study is looking for
- 18 years of age or older
- Diagnosed with one of the following at least 3 months prior to screening: schizophrenia or schizoaffective disorder, bipolar disorder, or major depressive disorder
- Diagnosed with at least mild neuroleptic-induced TD for at least 3 months prior to screening
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (19)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.